Australia markets closed

Vertex Pharmaceuticals Incorporated (VRTX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
480.73+1.70 (+0.35%)
At close: 04:00PM EDT
480.25 -0.48 (-0.10%)
After hours: 07:22PM EDT
Annual

Cash flow

All numbers in thousands
Breakdown
ttm
31/12/2023
31/12/2022
31/12/2021
31/12/2020
31/12/2019
Cash flows from operating activities
Net income
4,019,400
3,619,600
3,322,000
2,342,100
2,711,700
-
Depreciation & amortisation
196,000
181,300
148,300
125,600
109,500
-
Deferred income taxes
-581,400
-536,500
-275,900
-154,600
277,300
-
Stock-based compensation
650,700
581,200
491,300
441,400
429,500
-
Change in working capital
-275,300
-265,700
340,800
-105,200
-54,400
-
Accounts receivable
-245,200
-84,100
-358,600
-274,700
-223,400
-
Inventory
-320,400
-322,900
-136,400
-92,800
-132,000
-
Accounts payable
13,100
48,700
120,800
31,900
51,300
-
Other working capital
3,479,300
3,278,900
3,925,200
2,408,500
2,993,700
-
Other non-cash items
-99,400
-43,200
-45,700
11,300
91,800
-
Net cash provided by operating activities
3,944,000
3,537,300
4,129,900
2,643,500
3,253,500
-
Cash flows from investing activities
Investments in property, plant and equipment
-464,700
-258,400
-204,700
-235,000
-259,800
-
Acquisitions, net
-
0
-295,900
0
0
-
Purchases of investments
-4,574,500
-3,817,500
-740,500
-605,200
-450,700
-
Sales/maturities of investments
1,594,700
934,200
920,000
499,300
809,900
-
Net cash used for investing activities
-3,444,500
-3,141,700
-321,100
-340,900
99,400
-
Cash flows from financing activities
Debt repayment
-47,500
-44,900
-85,500
-47,000
-42,300
-
Common stock issued
-
-
-
-
-
343,244
Common stock repurchased
-719,000
-653,700
-172,000
-1,561,300
-739,400
-
Other financing activities
-
-
3,500
5,700
-1,800
4,800
Net cash used provided by (used for) financing activities
-625,000
-562,200
-67,700
-1,478,000
-505,300
-
Net change in cash
-126,200
-139,700
3,711,900
811,200
2,868,200
-
Cash at beginning of period
9,295,600
10,512,000
6,800,100
5,988,900
3,120,700
-
Cash at end of period
9,170,100
10,372,300
10,512,000
6,800,100
5,988,900
-
Free cash flow
Operating cash flow
3,944,000
3,537,300
4,129,900
2,643,500
3,253,500
-
Capital expenditure
-464,700
-258,400
-204,700
-235,000
-259,800
-
Free cash flow
3,479,300
3,278,900
3,925,200
2,408,500
2,993,700
-